Influence of Bifidobacterium breve on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial

Abstract

Type 2 diabetes mellitus (T2DM) is one of the most highly prevalent metabolic disorders worldwide. Uncontrolled T2DM can lead to other health threats such as cardiac arrest, lower-limb amputation, blindness, stroke, impaired kidney function, and microvascular and macrovascular complications. Many studies have demonstrated the association between gut microbiota and diabetes development and probiotic supplementation in improving glycemic properties in T2DM. The study aimed to evaluate the influence of Bifidobacterium breve supplementation on glycemic control, lipid profile, and microbiome of T2DM subjects. Forty participants were randomly divided into two groups, and they received probiotics (50 × 109 CFU/day) or placebo interventions (corn starch; 10 mg/day) for 12 weeks. The changes in the blood-urea nitrogen (BUN), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), creatinine levels, and other factors such as body-mass index, visceral fat, body fat, and body weight were assessed at baseline and after 12 weeks. B. breve supplementation significantly reduced BUN, creatinine, LDL, TG, and HbA1c levels compared to the placebo group. Significant changes were observed in the microbiome of the probiotic-treated group compared to the placebo group. Firmicutes and proteobacteria were predominant in the placebo and probiotic-treated groups. Genera Streptococcus, Butyricicoccus, and species Eubacterium hallii were significantly reduced in the probiotic-treated group compared to the placebo. Overall results suggested that B. breve supplementation could prevent worsening of representative clinical parameters in T2DM subjects. The current study has limitations, including fewer subjects, a single probiotic strain, and fewer metagenomic samples for microbiome analysis. Therefore, the results of the current study require further validation using more experimental subjects.

Comparison of the efficacy of fish oil and probiotic supplementation on glucose and lipid metabolism in patients with type 2 diabetes: a systematic review and network meta-analysis

“… 34 56.1 ± 8.2 Placebo 12 weeks 2 Mirjalili [ 72 ] Iran 36 54.5 ± 8.0 B.,L. 36 58.1 ± 9.8 Placebo 12 weeks 2–4 Chaiyasut[ 73 ] Thailand 20 63.9 ± 1.4 B. 20 61.1 ± 1.8 Placebo 12 weeks 2–4 Savytska [ 74 ] Ukraine 34 53.8 ± 9.6 B.L.La.P.…”

“…In the subgroup with intervention duration ≥ 12 weeks, the combination of Bifidobacterium, Lactobacillus, and Lactococcus was the most effective in reducing TG, followed by Bifidobacterium and fish oil. However, it is important to note that in this subgroup, the combination of Bifidobacterium, Lactobacillus and Lactococcus was only used in the study by Sabico [ 58 ], and Bifidobacterium was only reported in the study by Chaiyasut [ 73 ]. Since the two interventions was only used in one study, respectively, our results may be biased due to limited data, and publication bias may exist.…”

Investigating the causal association between gut microbiota and type 2 diabetes: a meta-analysis and Mendelian randomization

“…A flow chart of the screening process was shown in Figure 2 . The six included in the literature Kanazawa et al ( 28 ), Chaiyasut et al ( 29 ), Khalili et al ( 30 ), Rustanti et al ( 31 ), Toejing et al ( 32 ), Firouzi et al ( 33 ) were all RCT trials, and their interventions included gut probiotics.…”

Identifying gut microbiota with high specificity for ischemic stroke with large vessel occlusion

“…Furthermore, the present study found significant correlations between the relative abundances of genus Bifidobacterium and species Bifidobacterium_longum and the serum TG and HCY levels. This suggested that these microbes might be associated with lipid and homocysteine metabolisms in the early stage of LVO stroke 24 , 27 – 29 . Meanwhile, in our analyses, the serum TG levels of LVO patients could mediate the effects of species Bifidobacterium_longum on the ischemic stroke severity and functional outcome at discharge, which also provided a new insight on high TG as the risk factor of stroke 30 , 31 .…”